Melissa K Accordino

20PUBLICATIONS
189CO-AUTHORS
Haematological tumoursMolecular targetsMultimorbidityCancer cell biologyChemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Apr 18, 2026
Thrombosis Across Female-Specific Malignancies: From Chemotherapy-Driven Risk to Prophylaxis and Drug Interactions.

|Oct 27, 2025
PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.

Dejan Juric, Kyung Song, Radia M Johnson

|Oct 07, 2025
Where Have We Been and Where Are We Going? The State of the Hematology and Medical Oncologist Workforce in America.

M Kelsey Kirkwood, Erin P Balogh, Melissa K Accordino

|Oct 06, 2025
ASCO State of Cancer Care in America Special Report 2025: Access to Cancer Clinical Trials in the United States.

Erin P Balogh, Laura A Levit, Joseph M Unger

|Sep 30, 2024
Pharmacist-Led Video Consultation to Identify and Mitigate Drug Interactions Among Patients Initiating Oral Anticancer Drugs.

Morgan R L Lichtenstein, Peter Campbell, Rohit Raghunathan

|Sep 05, 2024
Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer.

Komal L Jhaveri, Melissa K Accordino, Philippe L Bedard

Pageof 4

Frequent Collaborators

9 joint publications

Dawn L Hershman

6 joint publications

Kevin M Kalinsky

6 joint publications

Jason D Wright

5 joint publications

Katherine D Crew